BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 27, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Afatinib: Phase III started

Boehringer began the open-label, international Phase III LUX-Breast 1 trial in about 780 HER2-positive breast cancer patients evaluating weekly 25 mg/m 2 IV vinorelbine and either once-daily oral afatinib or weekly 2...

Read the full 136 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >